ReviewClinical therapeutics2017
Prospects and Challenges in the Development of a Norovirus Vaccine.
Review in Clinical therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 115 citations in OpenAlex.
- Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach.Osong public health and research perspectives · 2025Article
- Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus.Virology journal · 2025Article
- Identification of Co-29, a 5-cyano-2-thiacetyl aromatic pyrimidinone, as a potential inhibitor targeting the RdRp of norovirus.Virology journal · 2025Article
- Molecular Characterization of Noroviruses Causing Acute Gastroenteritis Outbreaks among US Military Recruits, 2013-2023.Emerging infectious diseases · 2024Article
- A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.NPJ vaccines · 2024Review
- Predicting Dominant Genotypes in Norovirus Seasons in Japan.Life (Basel, Switzerland) · 2023Article
- Immunogenicity and Blocking Efficacy of Norovirus GII.4 Recombinant P Protein Vaccine.Vaccines · 2023Article
- Gastrointestinal Infection in South African Children under the Age of 5 years: A Mini Review.Gastroenterology research and practice · 2023Review
- Generation of Recombinant Rotaviruses Expressing Human Norovirus Capsid Proteins.Journal of virology · 2022Article
- Tuft-cell-intrinsic and -extrinsic mediators of norovirus tropism regulate viral immunity.Cell reports · 2022Article
- Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection.Viruses · 2022Article
- Unveiling of Pyrimidindinones as Potential Anti-Norovirus Agents-A Pharmacoinformatic-Based Approach.Molecules (Basel, Switzerland) · 2022Article
- Norovirus Vaccines: Current Clinical Development and Challenges.Pathogens (Basel, Switzerland) · 2021Review
- Chimeric VLPs Bearing VP60 from Two Serotypes ofVaccines · 2021Article
- Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design.Pathogens (Basel, Switzerland) · 2021Article
- Norovirus in Cancer Patients: A Review.Open forum infectious diseases · 2021Review
- Article
- Development and Application of a Novel Rapid and Throughput Method for Broad-Spectrum Anti-Foodborne Norovirus Antibody Testing.Frontiers in microbiology · 2021Article
- Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes.NPJ vaccines · 2020Article
- Vaccines against gastroenteritis, current progress and challenges.Gut microbes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeNorovirus is the leading cause of acute epidemic gastroenteritis among children under the age of 5 years and adults in the United States and in adults worldwide, accounting for an estimated 20% of episodes of acute gastroenteritis across all ages. No effective vaccine is presently available. This article provides an overview of the current state of norovirus vaccine development, emphasizing barriers and challenges in the development of an effective vaccine, correlates of protection used to assess vaccine efficacy, and the results of clinical trials of the major candidate vaccines.
methodsWe performed an unstructured literature review of published articles listed in PubMed in the field of norovirus vaccine development, with an emphasis on studies in humans.
findingsTwo candidate vaccines have reached clinical trials, and a number of other candidates are in the preclinical stages of development. Multivalent vaccination may be effective in inducing broadly neutralizing antibodies protective against challenge with novel and heterologous norovirus strains. Most identified correlates of protection have not been validated in large-scale challenge studies, nor have the degrees to which these correlates covary been assessed. IMPLICATIONS: Immune correlates of protection against norovirus infection need to be further developed to facilitate additional studies of the tolerability and efficacy of candidate norovirus vaccines in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.